Skip to main content
. Author manuscript; available in PMC: 2021 Aug 14.
Published in final edited form as: ACS Infect Dis. 2020 Jul 27;6(8):2017–2022. doi: 10.1021/acsinfecdis.0c00385

Figure 2.

Figure 2.

Anti-viral efficacy of VIQKI β3-variants against HPIV3 or RSV. Peptide activity against HPIV3 (left) or RSV (right) were determined by plaque reduction assay in infected Hep-2 cell monolayers. Data are shown as (A and B) percent inhibition of infection as a function of inhibitor concentration and (C and D) a ratio of the percent inhibition of each β3 variant with the percent inhibition of VIQKI. Gray zones represent the standard deviation of the VIQKI control. Data are expressed as mean ± standard deviation (n=3 separate experiments).